EAM
AKCA

Eventide Asset Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Eventide Asset Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-175,000
Closed -$4.48M – 153
2018
Q1 		$4.48M Sell
175,000
-245,000
-58% -$5.27M 0.21% 90
2017
Q4 		$7.29M Hold
420,000
– – 0.38% 70
2017
Q3 		$11.6M Buy
+420,000
New +$7.77M 0.66% 55

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eventide Asset Management's AKCA Position: Q2 2018 in Review

Eventide Asset Management sold out of Akcea Therapeutics Inc (AKCA) in Q2 2018, closing a stake of 175,000 shares — an estimated $4.48M sold.

Eventide Asset Management first reported a position in AKCA in Q3 2017 and held it in 3 quarters. The position peaked at $11.6M in Q3 2017. 56 funds tracked by Wall St. Rank hold AKCA as of Q2 2018.

  • Eventide Asset Management reported no remaining Akcea Therapeutics Inc position as of Q2 2018 after selling out during the quarter.
  • Eventide Asset Management sold 175,000 Akcea Therapeutics Inc shares in Q2 2018, an estimated $4.48M.
  • Eventide Asset Management first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 3 quarters.
  • Eventide Asset Management's Akcea Therapeutics Inc position peaked at $11.6M in Q3 2017.
  • 56 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q2 2018.

Based on Eventide Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.